1610885-17-0

Upstream product

• 726174-52-3 (6-hydroxy-benzofuran-3-yl)-acetic acid methyl ester 
• 805250-17-3 (6-hydroxy-2,3-dihydro-benzofuran-3-yl)-acetic acid methyl ester 
• 1003048-72-3 4-bromo-7-fluoro-2,3-dihydro-1H-inden-1-one 
• 1458652-57-7 (S)-4-bromo-7-fluoro -2,3-dihydro-1H-inden-1-ol 
• 1458652-58-8 methyl 2-((S)-6-((R)-4-bromo-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458652-59-9 methyl 2-((S)-6-((R)-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 3939-09-1 2,4-difluorobenzonitrile 
• 1610884-31-5 {(S)-6-[(R)-7-fluoro-4-hydroxy-indan-1-yloxy]-2,3-dihydro-benzofuran-3-yl}-acetic acid methyl ester 
• 1000414-38-9 methyl ((3S)-6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate 
• 69716-04-7 2-(6-hydroxy-1-benzofuran-3-yl)acetic acid 

Relevant academic research and scientific papers

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the group (Het)Ar is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula (I), wherein the group (Het)Ar is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.